SCHEMBL374833

SCHEMBL374833

O=C(c1nc[nH]n1)N(Cc1ccc(F)c(OCC2CC2)c1)C1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 4/20 0.39
SLC6A5 Q9Y345 2/20 0.39
KCNH2 Q12809 3/20 0.38
GRM2 Q14416 3/20 0.38
SLC2A1 P11166 1/20 0.34
SCN9A Q15858 1/20 0.34
CYP3A4 P08684 1/20 0.34
MCHR1 Q99705 1/20 0.33
DUT P33316 1/20 0.33
REN P00797 1/20 0.33
XDH P47989 1/20 0.33
NSD2 O96028 1/20 0.32
ATXN2 Q99700 2/20 0.32
PIM1 P11309 1/20 0.32
PIM3 Q86V86 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
P2RX4 Q99571 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375173 0.89 SLC6A9 (0.42) SLC6A9SLC6A5KCNH2CYP3A4REN
SCHEMBL375116 0.88 KDM4E (0.40) SLC6A9SLC6A5KCNH2CYP3A4NSD2
SCHEMBL375110 0.86 SLC6A9 (0.53) SLC6A9SLC6A5KCNH2CYP3A4DUT
SCHEMBL375183 0.86 SLC6A9 (0.40) SLC6A9SLC6A5KCNH2CYP3A4REN
SCHEMBL375305 0.85 SLC6A9 (0.36) SLC6A9SLC6A5KCNH2CYP3A4NSD2
SCHEMBL375006 0.81 PDE4D (0.39) SLC6A9SLC6A5KCNH2REN
SCHEMBL375594 0.81 KCNH2 (0.39) SLC6A9SLC6A5KCNH2CYP3A4
SCHEMBL375432 0.79 EPHX1 (0.39) SLC6A9SLC6A5KCNH2GRM2CYP3A4
SCHEMBL375145 0.79 SLC6A4 (0.49) KCNH2CYP3A4
SCHEMBL375147 0.78 TACR1 (0.41) SLC6A9SLC6A5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 SLC6A9 8/4885SLC6A5 4/4885KCNH2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.